🇺🇸 AZD6738 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 11

Most-reported reactions

1. Thrombocytopenia — 2 reports (18.18%)
2. Autoimmune Arthritis — 1 report (9.09%)
3. Cellulitis — 1 report (9.09%)
4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy — 1 report (9.09%)
5. Colitis — 1 report (9.09%)
6. Drug-Induced Liver Injury — 1 report (9.09%)
7. Dyspnoea — 1 report (9.09%)
8. Febrile Neutropenia — 1 report (9.09%)
9. Guillain-Barre Syndrome — 1 report (9.09%)
10. Haemoptysis — 1 report (9.09%)

Source database →

Frequently asked questions

Is AZD6738 approved in United States?

AZD6738 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for AZD6738 in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.